This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
CJC-1295 DAC (5 mg Vial)
CJC-1295 DAC is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). The DAC modification enables persistent albumin binding, with an approximately eight-day half-life described in the cited human study[2]. By stimulating pituitary GHRH receptors, CJC-1295 DAC increases GH secretion and circulating IGF-1 in a dose-dependent manner[2].
Quick Reference
What is CJC-1295 DAC?
Research overview based on the cited scientific literature.
• Goal: Support sustained GH and IGF-1 elevation for research into GH-axis effects[1].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Proper storage preserves peptide quality.
• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for 2–4 weeks; avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.
How is CJC-1295 DAC studied?
CJC-1295 DAC mimics endogenous GHRH, binding to GHRH receptors on pituitary somatotrophs to drive GH release[2]. The DAC modification (albumin-binding moiety) keeps the GHRH analog circulating for days rather than minutes, extending the half-life to approximately 6–8 days[1]. The resulting GH surge stimulates IGF-1 production (primarily in the liver); IGF-1 then mediates many growth and metabolic effects through JAK/STAT signaling pathways[4]. Notably, pulsatile GH secretion persists even during continuous CJC-1295 stimulation, preserving physiological release patterns[2].
What does the research report about CJC-1295 DAC?
Observations from preclinical and clinical literature.
• Clinical studies in healthy adults found sustained, dose-dependent elevations in GH and IGF-1 following CJC-1295 exposure[1].
• GH/IGF-1 physiology is associated with broader anabolic and metabolic effects, including regulation of protein and lipid metabolism[3][8].
• Growth-hormone signaling is associated with increased amino-acid uptake and protein synthesis and with effects on lipid metabolism[3].
• CJC-1295 was generally well tolerated in the cited healthy-adult clinical study, with no serious adverse reactions reported[1].
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
Research FAQs
1 What did the cited healthy-adult studies measure?
The studies measured CJC-1295 exposure and changes in circulating growth hormone and IGF-I, with safety observations during the study periods[1][2].
2 Do hormone changes prove broader clinical benefits?
Not by themselves. Changes in hormone concentrations are different outcomes from demonstrating improvements in sleep, recovery, body composition or long-term health. Those claims require studies that directly test those outcomes[1][2].
What are the limitations of the research on CJC-1295 DAC?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
